LIMES Schlosskliniken

LIMES Schlosskliniken operates a network of high-end private clinics specializing in psychiatry, psychosomatics, and psychotherapy. The company focuses on individualized treatment for mental health and stress-related conditions. As of June 2024 it runs at approximately a 90% occupancy rate with strong pricing power and has expanded through acquisition and organic growth.

Clinical results are not reported in the traditional biotech sense; success metrics are based on occupancy rates and patient outcomes within the context of private healthcare delivery.

The company acquired a majority stake in Paracelsus clinic in Switzerland in November 2021 to expand its reach to ultra-high-net-worth individuals.

Revenue for FY2023 was approximately $39 million USD, with projections for EUR ~50 million revenue by end of FY2025 as new clinics open.

As of early/mid–2025 it operates five core clinics across Germany and Switzerland with further expansion planned.

No drug development or clinical trial pipeline exists as the business model centers around care delivery rather than pharmaceutical R&D.